29 / 32
100c
100c
29
Biomonitoring
The Zenit product range includes all of the most innovative
technologies for detecting everything relevant to the diagnosis
and monitoring of autoimmune diseases.
…and so muchmore
The development of biological drugs (i.e., antibo-
dies with unique characteristics and specificities)
is an important advance in the treatment of inflam-
matory conditions such as rheumatoid diseases
and inflammatory bowel diseases. However, ef-
ficacy can be hampered by the development
of anti-drug antibodies (ADAs). It is important to
monitor the levels of these so-called biologicals
during treatment. Most biologicals are relatively
expensive, and drug dose, response and efficacy
should be monitored on an individual basis.
Awareness of these issues has lead to the deve-
lopment of drug monitoring regimens to optimize
therapy both clinically and economically.
A. Menarini Diagnostics offers several monitoring
tools, reagents and services developed to measure
drug activity and ADAs.
Celiac disease and type 1 diabetes are autoimmune
disorders affecting the lining of the small intestine
in celiac disease and pancreatic beta-cells in type
1 diabetes.
Celiac disease is far more common in people with
type 1 diabetes than in the general population –
as many as 10% of children with type 1 diabetes
test positive for the antibodies that indicate celiac
disease, compared with only one 1% of children in
the general population. Moreover, a growing body
of research suggests type 1 diabetes is triggered by
exposure to gluten, the protein linked to celiac di-
sease, supporting the theory that the two disorders
share common genetic causes.
We are proud to offer an easy range of PCR end-
point kits, to detect the alleles associated to celiac,
ankylosing spondylitis and type 1 diabetes.
Optimizingtreatmentswithbiologicals? A. MenariniDiagnosticshas thebest solutionfor you.